SUN Pharmaceutical Industries Limited — Lisinopril Exporter Profile
Indian Pharmaceutical Exporter · #9 for Lisinopril · $666.6K export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #9 Indian exporter of Lisinopril with $666.6K in export value and 68 verified shipments. SUN Pharmaceutical Industries Limited holds a 1.1% market share in Lisinopril exports across 2 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
SUN Pharmaceutical Industries Limited — Lisinopril Export Profile: Buyers & Destinations
Where Does SUN Pharmaceutical Industries Limited Export Lisinopril?
| Country | Value | Shipments | Share |
|---|---|---|---|
| BELGIUM | $532.8K | 44 | 77.8% |
| SOUTH AFRICA | $138.4K | 25 | 20.2% |
| NIGERIA | $14.0K | 3 | 2.0% |
SUN Pharmaceutical Industries Limited exports Lisinopril to 3 countries. The largest destination is BELGIUM accounting for 77.8% of SUN Pharmaceutical Industries Limited's Lisinopril shipments, followed by SOUTH AFRICA (20.2%) and NIGERIA (2.0%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Lisinopril from SUN Pharmaceutical Industries Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $485.4K | 41 |
| YUSEN LOGISTICS BENELUX | BELGIUM | $47.4K | 3 |
| RANBAXY S.A. (PTY) LTD ., | SOUTH AFRICA | $33.0K | 5 |
| RANBAXY S A PTY LTD | SOUTH AFRICA | $22.6K | 5 |
| RANBAXY S.A. (PTY) LTD., | SOUTH AFRICA | $21.6K | 2 |
| MERRITT GLOBAL LTD. | NIGERIA | $14.0K | 3 |
| RANBAXY PHARMACEUTICALS PTY LTD., | SOUTH AFRICA | $12.9K | 4 |
| RANBAXY SOUTH AFRICA PTY LTD | SOUTH AFRICA | $12.5K | 2 |
| RANBAXY S A (PTY) LIMITED | SOUTH AFRICA | $7.8K | 1 |
| RANBAXY S.A. (PTY) LIMITED . | SOUTH AFRICA | $7.3K | 1 |
SUN Pharmaceutical Industries Limited supplies Lisinopril to 15 buyers globally. The largest buyer is YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM), followed by YUSEN LOGISTICS BENELUX (BELGIUM) and RANBAXY S.A. (PTY) LTD ., (SOUTH AFRICA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Lisinopril Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?
India exported $15.9M worth of Lisinopril through 3,514 shipments from 221 suppliers to 94 countries, serving 450 buyers globally. SUN Pharmaceutical Industries Limited contributes $666.6K to this total, accounting for 1.1% of India's Lisinopril exports. SUN Pharmaceutical Industries Limited ships Lisinopril to 3 countries through 15 buyers.
What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Lisinopril Exports?
SUN Pharmaceutical Industries Limited's average Lisinopril shipment value is $9.8K per consignment, based on 68 shipments totaling $666.6K. The largest destination is BELGIUM (77.8% of SUN Pharmaceutical Industries Limited's Lisinopril exports).
How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Lisinopril Exporters?
SUN Pharmaceutical Industries Limited ranks #9 among 221 Indian Lisinopril exporters with a 1.1% market share. The top 3 exporters are LUPIN LIMITED ($4.3M), IPCA LABORATORIES LIMITED ($2.7M), MICRO LABS LIMITED ($1.9M). SUN Pharmaceutical Industries Limited processed 68 shipments to 2 destination countries.
What Lisinopril Formulations Does SUN Pharmaceutical Industries Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| LISINOPRIL TABLETS 10MG ( RANOLIP TABLET | $129.6K | 8 |
| LISINOPRIL TABLETS 20MG RANOLIP TABLETS 20MG EACH TABLET CONTAINS: LISINOPRIL DIHYDRATE PH.EUR EQ. TO LISINOPRIL ANH | $50.9K | 2 |
| LISINOPRIL TABLETS 20MG ( RANOPRIL TABLE | $33.3K | 2 |
| LISINOPRIL TABLETS 20MG ( RANOPRIL TABLETS 20MG ) EACH TABLET CONTAINS:LISINOPRIL DIHYDRATE PH.EUR EQ. TO LISINOPRIL ANH | $32.5K | 2 |
| LISINOPRIL TABLETS 10MG ( RANOPRIL TABLETS 10MG ) EACH TABLET CONTAINS: LISINOPRIL DIHYDRATE PH.EUR EQ. TO LISINOPRIL AN | $29.5K | 3 |
| LISINOPRIL TABLETS 20MG ( RANOLIP TABLET | $27.0K | 1 |
| LISINOPRIL TABLETS 5MG ( RANOPRIL TABLETS 5MG)PACK: BOX 2X14S BATCH:PTF6076A MFD:25.12.2024 EXP :30.11.2027 | $25.2K | 2 |
| LISINOPRIL TABLETS 10MG RANOLIP TABLETS 10MG EACH TABLET CONTAINS: LISINOPRIL DIHYDRATE PH.EUR EQ. TO LISINOPRIL ANH | $24.3K | 2 |
| LISINOPRIL TABLETS 20MG BATCH : PTF5913AMFD : 14.12.2024 EXP : 30.11.2027 | $23.9K | 1 |
| LISINOPRIL TABLETS 5MG ( RANOPRIL TABLET | $21.2K | 3 |
SUN Pharmaceutical Industries Limited exports 46 distinct Lisinopril formulations including tablets, capsules, syrups, and combination drugs. The top formulation is LISINOPRIL TABLETS 10MG ( RANOLIP TABLET with 8 shipments worth $129.6K.
Regulatory Requirements: Exporting Lisinopril to Key Markets
What SUN Pharmaceutical Industries Limited must comply with to export Lisinopril to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Nigeria — NAFDAC
Approval Process
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Timeline: 6–18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does SUN Pharmaceutical Industries Limited Compare to Nearest Lisinopril Exporters?
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 8 | MARKSANS PHARMA LIMITED | $936.1K | 47 | 1 | $19.9K |
| 1 | MYLAN LABORATORIES LIMITED | $800.0K | 16 | 1 | $50.0K |
| 9 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $666.6K | 68 | 2 | $9.8K |
| 10 | CIPLA LIMITED | $640.3K | 64 | 1 | $10.0K |
| 11 | WATSON PHARMA PRIVATE LIMITED | $505.3K | 17 | 1 | $29.7K |
SUN Pharmaceutical Industries Limited ranks #9 among 221 Indian Lisinopril exporters. Average shipment value of $9.8K compared to the market average of $72.1K. The closest competitors by value are MARKSANS PHARMA LIMITED and MYLAN LABORATORIES LIMITED.
Which Indian Ports Ship Lisinopril Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 597 | 17.0% |
| DELHI AIR CARGO ACC (INDEL4) | 514 | 14.6% |
| SAHAR AIR | 509 | 14.5% |
| DELHI AIR | 282 | 8.0% |
| NHAVA SHEVA SEA (INNSA1) | 238 | 6.8% |
| Bombay Air | 172 | 4.9% |
| HYDERABAD ICD (INSNF6) | 112 | 3.2% |
| Delhi Air | 110 | 3.1% |
Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Lisinopril Exports
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
About SUN Pharmaceutical Industries Limited
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Lisinopril, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Lisinopril — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Lisinopril shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 72 individual customs records matching SUN Pharmaceutical Industries Limited exporting Lisinopril, covering 46 formulations to 3 countries via 15 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 94+ countries, 450+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Lisinopril Export Data from SUN Pharmaceutical Industries Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Lisinopril exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
Lisinopril Stats
Company Overview
Top Products by SUN Pharmaceutical Industries Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Lisinopril. For current shipment-level data, contact TransData Nexus.